[{"orgOrder":0,"company":"PureIMS","sponsor":"Boost-UP Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PureIMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"PureIMS \/ Boost-UP Foundation","highestDevelopmentStatusID":"10","companyTruncated":"PureIMS \/ Boost-UP Foundation"},{"orgOrder":0,"company":"PureIMS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PureIMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"PureIMS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PureIMS \/ Inapplicable"},{"orgOrder":0,"company":"PureIMS","sponsor":"Cooperative Clinical Drug Research and Development AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PureIMS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureIMS \/ Cooperative Clinical Drug Research and Development AG","highestDevelopmentStatusID":"6","companyTruncated":"PureIMS \/ Cooperative Clinical Drug Research and Development AG"}]

Find Clinical Drug Pipeline Developments & Deals by PureIMS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cell Therapy
                          Not Confirmed
                          Cell Therapy
                          Not Confirmed

                          Details : Levodopa Cyclops™ is a levodopa dry powder inhaler which is being evaluated in phase 2 clinical trials for the fast and reliable relief of OFF episodes in Parkinson’s disease.

                          Product Name : Levodopa Cyclops

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 18, 2024

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Cell Therapy
                          Not Confirmed
                          Cell Therapy
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 14, 2023

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Cooperative Clinical Drug Research and Development AG

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Boulder Peptide
                          Not Confirmed
                          Boulder Peptide
                          Not Confirmed

                          Details : The funds will be used to develop lead program Levodopa Cyclops™ for US and EEA marketing, of which early clinical studies already demonstrated very rapid onset of action in combatting OFF-episodes in Parkinsons' disease.

                          Product Name : Levodopa Cyclops

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 04, 2023

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Boost-UP Foundation

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank